Home Clinical Topics FDA approves Synribo for chronic myelogenous leukemia
Clinical TopicsDrugs and DevicesHealthcare & TechnologyNewsOncologyWeb Exclusives

FDA approves Synribo for chronic myelogenous leukemia

Author(s):

On Oct. 26, the U.S. Food and Drug Administration (FDA) approved Synribo (omacetaxine mepesuccinate) for the treatment of adults with chronic myelogenous leukemia. Synribo blocks certain proteins that promote the development of cancerous cells. Read more.

Previous articleStudy: Reporting medical errors may help reduce them in multi-site clinical practices
Next articleWhat a Great Week For Midlife Women And Menopausal Hormone Therapy – Keeps And Dops!

RELATED ARTICLES

Clinical Topics

Catching up to stay ahead

Getting back on track with routinely recommended vaccinations The COVID-19 pandemic has resulted in dramatic declines in adolescent vaccinations, which began in March 2020 and...
Read more
Clinical Topics

Malignant hyperthermia

This potentially lethal condition calls for quick action.  Takeaways: Malignant hyperthermia is a genetic life-threatening disease that results in an uncontrolled release of calcium that...
Read more
Clinical Topics

Drug diversion in healthcare

Prevention and detection for nurses Special report to American Nurse Journal, supported by an educational grant from Fresenius Kabi USA. © 2021, HealthCom Media Takeaways: Drug diversion among...
Read more

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Early Release Articles

Powered by  HCM   www.HealthComMedia.com

© 2021 HealthCom Media All rights reserved. No part of this website or publication may be reproduced, stored, or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing from the copyright holder